相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Eleonore Beurel et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Mutant huntingtin alters Tau phosphorylation and subcellular distribution
David Blum et al.
HUMAN MOLECULAR GENETICS (2015)
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease
Maud Gratuze et al.
HUMAN MOLECULAR GENETICS (2015)
Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain
Nastasia K. H. Lim et al.
HUMAN MOLECULAR GENETICS (2014)
Preclinical and Clinical Investigations of Mood Stabilizers for Huntington's Disease: What Have We Learned?
Lisa Scheuing et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κI' and p70s6k, in patients with advanced solid tumors
D. S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2014)
Huntington's disease is a four-repeat tauopathy with tau nuclear rods
Marta Fernandez-Nogales et al.
NATURE MEDICINE (2014)
A Dopamine D2 Receptor-DISC1 Protein Complex may Contribute to Antipsychotic-Like Effects
Ping Su et al.
NEURON (2014)
Activator or inhibitor? GSK-3 as a new drug target
Fumi Takahashi-Yanaga
BIOCHEMICAL PHARMACOLOGY (2013)
Design of Glycogen Synthase Kinase-3 Inhibitors: An Overview on Recent Advancements
Minhajul Arfeen et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Effects of DNMT1 and HDAC Inhibitors on Gene-Specific Methylation Reprogramming during Porcine Somatic Cell Nuclear Transfer
Weihua Xu et al.
PLOS ONE (2013)
Neuronal Apoptosis and Motor Deficits in Mice with Genetic Inhibition of GSK-3 Are Fas-Dependent
Raquel Gomez-Sintes et al.
PLOS ONE (2013)
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
Orestes V. Forlenza et al.
BRITISH JOURNAL OF PSYCHIATRY (2011)
Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice
W. Timothy O'Brien et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease
Chi-Tso Chiu et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Regulation of glycogen synthase kinase-3 during bipolar mania treatment
Xiaohong Li et al.
BIPOLAR DISORDERS (2010)
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum
A. Saavedra et al.
CELL DEATH AND DIFFERENTIATION (2010)
BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease
A. Giralt et al.
GENE THERAPY (2010)
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy
Raquel Gomez-Sintes et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mutant Huntingtin and Glycogen Synthase Kinase 3-beta Accumulate in Neuronal Lipid Rafts of a Presymptomatic Knock-In Mouse Model of Huntington's Disease
Antonio Valencia et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2010)
A critical appraisal of lithium's efficacy and effectiveness: the last 60 years
Paul Grof et al.
BIPOLAR DISORDERS (2009)
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity
Xavier Xifro et al.
NEUROBIOLOGY OF DISEASE (2009)
A β-arrestin 2 signaling complex mediates lithium action on Behavior
Jean-Martin Beaulieu et al.
CELL (2008)
A feasibility and tolerability study of lithium in Alzheimer's disease
Alastair Macdonald et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2008)
The GSK3 hypothesis of Alzheimer's disease
Claudie Hooper et al.
JOURNAL OF NEUROCHEMISTRY (2008)
A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin
Sovan Sarkar et al.
HUMAN MOLECULAR GENETICS (2008)
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice
Raquel Gomez-Sintes et al.
EMBO JOURNAL (2007)
Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans
Cindy Voisine et al.
PLOS ONE (2007)
Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model
Kei Watase et al.
PLOS MEDICINE (2007)
Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration
K. Leroy et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)
Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert
Tobias Engel et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders
Todd D. Gould et al.
CURRENT DRUG TARGETS (2006)
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways
Eleonore Beurel et al.
PROGRESS IN NEUROBIOLOGY (2006)
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3
Tobias Engel et al.
JOURNAL OF NEUROSCIENCE (2006)
Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway
Z Berger et al.
HUMAN MOLECULAR GENETICS (2005)
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
W Noble et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain
XH Li et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease
A Hye et al.
NEUROSCIENCE LETTERS (2005)
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade
JM Beaulieu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Pharmacological inhibitors of glycogen synthase kinase 3
L Meijer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling
HM Yang et al.
CIRCULATION (2004)
GSK3 inhibitors: Development and therapeutic potential
P Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells
S Gines et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation
NI Wood et al.
BRAIN RESEARCH BULLETIN (2003)
GSK-3: tricks of the trade for a multi-tasking kinase
BW Doble et al.
JOURNAL OF CELL SCIENCE (2003)
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments
F Hernández et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation
J Carmichael et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
CA Grimes et al.
PROGRESS IN NEUROBIOLOGY (2001)
Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice
JJ Lucas et al.
EMBO JOURNAL (2001)
Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease
H Wei et al.
NEUROSCIENCE (2001)
Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice
K Spittaels et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
